Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03185468

Intervention of Bladder Cancer by CAR-T

Intervention of Advanced or Metastatic Urothelial Bladder Cancer by 4SCAR-T Cell Therapies

Sponsor: Shenzhen Geno-Immune Medical Institute

Conditions Bladder Cancer Urothelial Carcinoma Bladder

Updated 8 times since 2017 Last updated: Sep 4, 2025 Started: Aug 1, 2025 Primary completion: Dec 31, 2028 Completion: Dec 31, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03185468, this PHASE1/PHASE2 trial focuses on Bladder Cancer and Urothelial Carcinoma Bladder and remains actively recruiting participants. Sponsored by Shenzhen Geno-Immune Medical Institute, it has been updated 8 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Oct 2025 — Present [monthly]

Recruiting PHASE1/PHASE2

Status: Unknown → Recruiting
Sep 2024 — Oct 2025 [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 3 earlier versions

Oct 2019 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2
Jun 2018 — Oct 2019 [monthly]

Recruiting PHASE1_PHASE2
Jul 2017 — Jun 2018 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shenzhen Geno-Immune Medical Institute

Data source: Shenzhen Geno-Immune Medical Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shenzhen, China